7-20-2002: The king of con | News | News from Fort Worth, Dallas, Arlington,...
4 days ago
"What they've found is just the tip of the iceberg," he says of the revelations at Enron, WorldCom and ImClone, among others.
Lawsuit alleges Merck discriminates against women
9 days ago
She wants to create a class action lawsuit on behalf of Merck's female sales representatives.
Merck: FDA reviewing its ragweed allergy therapy
10 days ago
Merck's latest application is for an allergy immunotherapy tablet for ragweed allergies that dissolves under the tongue.
News Summary: Generic rivals hurt Merck results
17 days ago
ON DECK: Merck has five drugs under review by regulators, including a promising insomnia medicine called suvorexant.
Stocks fall on jobs concerns, fall in Merck profit
17 days ago
The stock market is falling early after a survey showed U.S. companies added the fewest jobs in seven months and Merck reported a lower quarterly profit.
Generic competition cuts Merck's Q1 sales, profit
18 days ago
Merck's first-quarter profit fell 8.3 percent and revenue by 9 percent, mainly because competition from generics slashed sales of its top seller, asthma and allergy drug Singulair.
News Summary: Merck names ex-Amgen exec to run R&D
72 days ago
COMING BACK: Dr. Roger Perlmutter, a former research executive at drugmaker Merck & Co., will return on April 15 to become director of Merck Research Laboratories.
Merck replacing R&D head with former company exec
72 days ago
The world's third-biggest drugmaker by revenue says Dr. Roger Perlmutter, a former research executive at Merck and Amgen Inc., will begin running Merck Research Laboratories on April 15.
Merck settles investor suits on cholesterol drugs
93 days ago
When Merck in early 2008 finally released study results showing the pricey drugs didn't work better than an inexpensive generic pill, Merck stock tumbled, causing big losses for investors.
Analyst downgrades Merck on concerns over 2 drugs
103 days ago
Merck, based in Whitehouse Station, N.J., said Friday it won't apply for approval of its odanacatib (oh-DAN'-eh-cat-ib), a new type of osteoporosis drug, until 2014 instead of early this year.
